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Abstract: Drug delivery systems such as nanoparticles can provide enhanced efficacy for 
  anticancer agents. Noscapine, a widely used cough suppressant for decades has recently been 
shown to cause significant inhibition and regression of tumor volumes without any detectable 
  toxicity in cells or tissues. Nanoparticles made of human serum albumin (HSA) represent 
  promising strategy for targeted drug delivery to tumor cells by enhancing the drug’s bioavail-
ability and distribution, and reducing the body’s response towards drug resistance. In the   present 
study, we report for the first time the incorporation and delivery of noscapine-loaded HSA 
nanoparticles to tumor cells. The nanoparticles were designed and optimized to achieve a particle 
size in the range of 150–300 nm with a drug-loading efficiency of 85%–96%. The nanoparticles 
were evaluated in vitro for their anticancer activity and efficacy on breast cancer cells.
Keywords: HSA, encapsulation, microcapsule, nanomedicine, nanotechnology, tumor 
volumes
Introduction
Most commonly used chemotherapeutic drugs such as paclitaxel interact with   tubulin, 
the major protein of mitotic spindles, causing growth arrest in metaphase. These agents 
induce the polymerization of tubulin and stop mitosis of rapidly dividing cells; thereby 
leading to apoptosis. Despite impressive results, available chemotherapeutic drugs 
have severe symptoms associated with them including myelosuppresion.1 Also as 
a result of repeated and prolonged administration of chemotherapeutic agents, drug 
resistance can occur.1,2 In addition, these drugs are toxic to healthy tissues, and have 
poor bioavailability that results in the need of extended intravenous infusions and the 
use of toxic solubility agents.1,3
Noscapine, a phthalide isoquinoline alkaloid derived from opium, has been used as 
an oral antitussive agent and has shown very few toxic effects in animals and humans. 
It is a naturally occurring tubulin-binding agent currently undergoing clinical trials for 
anticancer therapy. Noscapine, which lacks sedative, analgesic, and euphoric proper-
ties, has been used for decades as a cough suppressant. Noscapine showed little or 
no toxicity on kidney, liver, heart, bone marrow, spleen, and small intestine at tumor 
suppressive doses.4 Noscapine was also shown to cause growth arrest of tumor cells 
during mitosis and induces apoptosis5–7 and can therefore be used as an alternative 
to current chemotherapeutic drugs.8–10 It was recently reported that noscapine was 
  effective in reducing the growth of lymphoma and increasing the survival of tumor-
bearing mice when administered in their drinking water.7,11–15 However, current drug 
delivery methods of high concentration of noscapine are inadequate.International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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To increase the concentration of noscapine at the 
tumor site, we have encapsulated noscapine into colloidal 
drug nanocarriers made of human serum albumin (HSA). 
  Nanoparticles of minimal size can enhance the efficacy of 
drug metabolism with minimal side effects since they allow 
for the possibility of site-specific targeted delivery.16–18 
Nanoparticles also offer benefits to carry functional groups 
(amino and carboxylic groups) that can be used for surface 
modifications. The emergence of nanoscaled devices as 
drug delivery systems has been remarkable in such a short 
span of time and has surpassed conventional methods of 
drug delivery. Nanoparticles help to increase the stability 
of drugs and possess useful controlled release properties. 
HSA-based nanoparticles can be well tolerated without any 
serious side effects, which is supported by clinical studies 
with registered HSA-based particle formulations such as 
Albunex.18–21 Albumin has been shown to be biodegradable, 
nontoxic, easy to purify, and soluble in water, allowing 
ease of delivery by injection and thus an ideal candidate for 
nanoparticle preparation. Incorporation of suitable drugs in 
nanoparticles has been shown to protect the pharmacological 
active substances from degradation during storage as well as 
from early degradation/inactivation after injection.22–24
Many different possibilities have been discussed and 
tested to reduce the toxicity and increase antitumor efficacy 
of anticancer drugs using nanodevices.25–27 Encapsulating 
noscapine in nanoparticles will help to increase its efficacy 
and lowers any side effects. In this paper we report for the 
first time encapsulation of noscapine into HSA nanoparticles 
with a described protocol on optimization of drug loading 
and preparation of nanoparticles and their effectiveness on 
breast cancer cell line (SK-BR-3).
Materials and methods
Materials
Human serum albumin (HSA fraction V , purity 96%–99%), 
noscapine hydrochloride and 8% glutaraldehyde, were 
  purchased from Sigma Aldrich (Oakville, Ontario, Canada). 
For cell culture, fetal bovine serum (FBS), trypsin, McCoy’s 
5a medium, penicillin/streptomycin, and the SK-BR-3 cell 
line were purchased from American Type Culture   Collection 
(Ontario, Canada). Cell-line was cultured according to 
  supplier’s instructions. All other reagents were purchased 
from Fisher (Ontario, Canada).
Preparation of noscapine nanoparticles
Drug-free HSA nanoparticles and noscapine-loaded 
  nanoparticles crosslinked with glutaraldehyde were   prepared 
using a pH-coacervation method.28,29 100 mg of HSA 
was dissolved in 2 mL of water or NaCl. Noscapine at a 
  concentration of 5–30 mg/mL was incubated with   solution for 
4–8 h at room temperature.30 The pH was adjusted to 8 by the 
addition of 1 M NaOH. Nanoparticles were formed by adding 
8 mL of ethanol drop-wise at a constant rate of 1 mL/min 
under constant magnetic stirring. The   particles were sta-
bilized by crosslinking with 100 µL of 8%   glutaraldehyde 
solution. The crosslinking was performed for at least 24 h 
under constant magnetic stirring at room temperature.30,31 
Drug loading was evaluated following an indirect method of 
collecting the supernatant of purified particles. The quantity 
of unloaded free drug present in the supernatant was mea-
sured by spectrophotometer that lead to the quantification of 
the percentage of drug loaded into the nanoparticles.
Purification of HSA nanoparticles
The resulting albumin nanoparticles were purified by 
three cycles of ultra-centrifugation (20,000 g, 30 min) 
followed by redispersion of pellet in water to original 
volume. Each redispersion step was performed in an 
  ultrasonication bath (Branson 2510; Bransonic, Danbury, 
CT) for 15 min.
Particle size and zeta potential 
of nanoparticles
The size of noscapine albumin nanoparticles was   determined 
by photon correlation spectroscopy (PCS) using a high 
performance particle size analyzer (Malvern Instruments, 
Westborough, MA). The samples were diluted with distilled 
water and measured at 25°C at a   scattering angle of 90°. Size 
distribution was characterized by a polydispersity index (PI) 
and the zeta potential was measured with the technique of 
electrophoretic laser     Doppler anemometry, using a Zeta 
Potential Analyzer (Brookhaven Instruments, Holtsville, 
NY).   Morphological characteristics were examined using 
scanning electron microscope (Hitachi S-4700 FE-SEM; 
Hitachi, Tokyo, Japan). In order to determine the stability 
of the   nanocarriers when dispersed in aqueous solution, 
they were stored at room temperature for 5 days while being 
regularly monitored for size and zeta potential each day. The 
size and shape of the nanoparticles were also   examined by 
scanning electron microscopy (SEM).
Drug release profile of noscapine-loaded 
hSA nanoparticles
Determination of drug release of noscapine was performed 
by dispersing 10 mg of noscapine-loaded nanoparticles International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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in 10 mL phosphate-buffered saline (PBS; pH 7.4) under 
  constant shaking at 200 rpm/min at 37°C. The samples were 
centrifuged and the amount of free noscapine in the super-
natant was determined at predefined time intervals using a 
UV spectrophotometer Victor3 V 1420 Multilabel Counter 
(Perkin Elmer, Boston, MA) at 310 nm. This analysis was 
performed three times for each sample.
cell culture
SK-BR-3 cells were grown in McCoy’s 5a medium with 10% 
FBS and 1% penicillin/streptomycin. Cells were cultured in 
a humidified incubator containing 5% CO2 at 37°C.
In vitro cell viability of noscapine-loaded 
hSA nanoparticles
The determination of cell viability is a common assay to 
evaluate the in vitro cytotoxicity of biomaterials. The MTS 
assay is a quantitative and rapid colorimetric method for 
measuring the viability of cells. The cytotoxicity study of the 
nanoparticles was examined in vitro on the breast cancer cell-
line SK-BR-3; the cell lines were cultured in 96-well plates at 
an initial concentrations of 5000 cells/well in fresh medium 
supplemented with 10% FBS. The cell proliferation was 
determined by cell counting after trypsinization and trypan 
blue staining. After 24 h of culture, cells were adherent and 
the medium was replaced by noscapine-loaded nanoparticles 
at a final concentration of 50 µg/mL. The media was removed 
after 24 h and replaced with fresh medium supplemented with 
10% FBS. The cell viability and cytotoxicity were determined 
using MTS cell proliferation kit. At predetermined time inter-
vals, 20 µl of MTT was added in each well and incubated for 
4 h in a humidified incubator containing 5% CO2 at 37°C and 
absorbance was measured at 490 nm using a Victor3V 1420 
Multilabel Counter spectrophotometer (Perkin Elmer).32–34
Results and discussion
Preparation and visualization  
of noscapine nanoparticles
The objective of the present study was to design HSA 
  nanoparticles for noscapine delivery and establish a stan-
dard protocol for their preparation. HSA nanoparticles 
  containing noscapine were prepared by coacervation method, 
in which ethanol was used as a dissolving agent, followed 
by   crosslinking using glutaraldehyde.29 The pH-coacervation 
method has widely been used in the encapsulation of both 
water-soluble and insoluble drugs. Initially we investigated 
the effect of the process conditions such as the aqueous HSA 
concentration, the rotation speed of the magnetic stirrer, the 
pH of the solution prior to ethanol addition, and the rate of 
ethanol addition. After experimentation and optimization a 
final preparation method was prepared. Uniform particles 
with narrower size distribution were achieved at higher 
rotation speed of the magnetic stirrer with ethanol, dropped 
at a constant flow rate using a peristaltic pump. With the 
modified pH-coacervation technique reported in this study, 
we achieved noscapine-loaded HSA nanoparticles of diam-
eters between 150 and 300 nm and narrow size distribution 
determined by the PI of , 0.4. The SEM micrographs reveal 
morphological aspects of nanoparticles with a spherical 
shape and uniform size distribution in the desired range of 
nanoparticle sizes (Figure 1).
Degree of crosslinking  
of   noscapine-loaded nanoparticles
Crosslinking of nanoparticles with a crosslinking agent can 
limit their degradation rate and hydration potential, thereby 
attaining slow-release kinetics.35,36 The influence of the cross-
linking process (glutaraldehyde concentration, 50%–200%) 
on the size of albumin nanoparticles was investigated. This 
process plays a major role in the stability and drug release of 
albumin nanoparticles. Figure 2 shows the effect of different 
glutaraldehyde concentrations on particle diameter and PI of 
noscapine-loaded nanoparticles. The results reveal that the 
concentration of glutaraldehyde had little or no effect on 
particle size or polydispersity.
Influence of pH and crosslinking on size 
and zeta potential of hSA nanoparticles
It was found that the pH of the noscapine-HSA solution 
prepared prior to ethanol addition was a crucial factor in 
Figure 1 Scanning electron micrograph of glutaraldehyde crosslinked nanoparticles 
prepared at ph 8, 60k resolution. The nanoparticles were found to be of uniform 
size and narrow size distribution.International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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Figure 2 effect of glutaraldehyde concentration on diameter and polydispersity index of noscapine (5 mg/mL) loaded human serum albumin (hSA) nanoparticles prepared 
with 10 mM Nacl solution and 100 mg of hSA protein at ph 8.
affecting the particle size of the resulting nanoparticles 
(Figure 3). At pH 5–7, particles were of larger diameter with 
high polydispersity indices. The particle size was greatest 
at pH 7 at approximately 2500 nm. At pH greater than 7 
the particle diameter was reduced and at pH 8 the particles 
had optimal size and narrow size distribution at approxi-
mately 175–200 nm. The nanoparticles prepared at higher 
pH of 8–8.2, when viewed under SEM, revealed uniform 
and spherical particles.
The electrical behavior of the noscapine-loaded HSA 
nanoparticles was also evaluated at different pH (Figure 3). 
Higher surface charge was attained on HSA nanoparticles 
by increasing the pH of the HSA solution. It was observed 
that with increasing pH . 7, the surface charge of prepared 
nanoparticles was reduced; particles prepared at pH 8 had 
their surface charge reduced to -47mV . It was noted that 
preparation of particles at higher pH also leads to repulsion 
among the HSA molecules due to steric effect and lead to 
aggregation during particle formation.
The stability of the nanoparticles was also investigated. 
Noscapine-loaded nanoparticles prepared at pH 8.2 were 
stored for 5 days in water at 4°C and at predefined times the 
samples were analyzed with regard to size (Figure 4). The 
particle size increased slightly to 190 nm, but particles were 
found to be stable after 5 days.
Investigation of noscapine delivery 
by nanoparticles
Noscapine was adsorbed to HSA in solution prior to 
  nanoparticle preparation. The pH was adjusted to 8.2 at 
different noscapine concentrations ranging from 5 mg/mL 
to 30 mg/mL of HSA. All preparations were stabilized 
with glutaraldehyde. Figure 5 illustrates the encapsulation 
efficiency of HSA nanoparticles at different drug concentra-
tions. Maximum encapsulation was attained at noscapine 
concentrations of 5 mg/mL with an efficiency of 97%. 
Encapsulation efficiency was shown to gradually decrease 
with increasing drug concentration. The lowest encapsula-
tion efficiency was seen at noscapine concentrations of 
25 mg/mL and 30 mg/mL suggesting that at higher con-
centrations of noscapine more incubation time is probably 
required as well as greater concentration of HSA is needed 
for efficient encapsulation.
The drug release profiles of noscapine-loaded HSA 
  nanoparticles were also investigated. Noscapine albumin 
nanoparticles prepared under experimental conditions 
described previously were tested in vitro and released at 
37°C in PBS at pH 7.4. It was found that with increasing 
drug concentrations the particle size and polydispersity 
increased dramatically. Figure 6 shows the in vitro release of 
  cumulative amounts of noscapine from   albumin   nanoparticles International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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Figure 4 Stability of noscapine (5 mg/mL) loaded human serum albumin (hSA) 
nanoparticles over 5 days. Particle size was monitored. Noscapine-loaded HSA 
nanoparticles prepared with 10 mM Nacl solution and 100 mg of hSA protein 
at ph 8.
as a function of time. For noscapine   concentrations of 
5 mg/mL, the initial drug released was around 10% which 
was considered a biphasic way of release; it is character-
ized by an initial rapid release period followed by a step 
of slower release. For noscapine-loaded nanoparticles with 
noscapine concentrations of 5 mg/mL and 10 mg/mL, the 
release profile was slow after 72 h, with less than 30% of the 
drug being released. While at concentrations of 15 mg/mL of 
noscapine more than 60% of the drug had been released after 
72 h. The release profile seemed moderately slow.
Viability of hSA nanoparticles loaded 
with noscapine in a SK-BR-3 cell line
HER-2 positive SK-BR-3 breast cancer cells were used to 
examine the efficacy of noscapine prepared   nanoparticles. 
The cell lines were cultured in 96-well plates at an 
  initial   concentration of 5000 cells/well in fresh medium. 
After 24 h of culture, cells were adherent, and medium 
was replaced with prepared noscapine nanoparticles and 
  drug-free HSA   nanoparticles. We analyzed the cell viability 
and cytotoxicity of noscapine-loaded nanoparticles pre-
pared at noscapine concentrations of 5, 10, and 15 mg/mL, 
and compared them with drug-free nanoparticles. Both 
drug-loaded and drug-free nanoparticles were added 
in SK-BR-3 breast cancer cell lines over time periods of 24, 
48, 72, 96, and 144 h (Figure 7). As expected the efficacy of 
the particles depended on the concentration of drug-loaded. 
Noscapine nanoparticles with concentrations of 5 mg/mL 
had the lowest efficacy with cell viability of 60% after 
144 hrs. The cell viability was less than 35% for noscapine 
nanoparticles prepared with noscapine concentrations of 10 
and 15 mg/mL after 144 h. The drug-free nanoparticles had International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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Figure 5 Noscapine encapsulation of human serum albumin nanoparticles (50 mg/mL) in dependence on noscapine concentration.
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Figure 6 Drug release profile of noscapine-loaded human serum albumin (HSA) nanoparticles (noscapine concentration 5–15 mg/mL) over predetermined time intervals. 
Noscapine-loaded HSA nanoparticles prepared with 10 mM NaCl solution and 100 mg of HSA protein at pH 8.
little effect on the cell viability of the cells, and after 48 h 
the cell viability of cells with drug-free nanoparticles was 
approximately 93%. Gradually, the viability of cells treated 
with drug-free nanoparticles slightly decreased to about 80% 
after 144 h. Hence noscapine-loaded nanoparticles could 
potentially be used in the treatment of tumor cells.
Conclusion
HSA nanoparticles can be successfully used to encapsulate 
noscapine and be prepared by the coacervation method. 
Preparation pH appeared to have an influence on size 
and particle yield; however it did not induce any effect in 
the drug-loading capacity. In addition, the in vitro drug 
delivery studies indicated controlled slow release profiles. 
In   conclusion noscapine-loaded HSA nanoparticles have the 
potential to be used to deliver a maximum amount of noscap-
ine to target sites at a rate and concentration that permits 
optimal therapeutic efficacy, while reducing any undesirable 
side effects to a minimum. Further experiments using surface 
modification of noscapine nanoparticles are being conducted 
for tumor cell-specific targeting applications, and for further 
evaluation of cell cytotoxicity and efficacy in cancer cells.
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